STOCK TITAN
  1. Home
  2. News
  3. IVBIY

Innovent Biologics Inc - IVBIY STOCK NEWS

Welcome to our dedicated news page for Innovent Biologics (Ticker: IVBIY), a resource for investors and traders seeking the latest updates and insights on Innovent Biologics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Innovent Biologics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Innovent Biologics's position in the market.

News
Innovent's First New Drug Application of Mazdutide for Chronic Weight Management has been Accepted by the NMPA of China
Rhea-AI Summary
Innovent Biologics, Inc. announces the acceptance of the New Drug Application (NDA) for mazdutide, a GLP-1R/GCGR dual agonist, by the National Medical Products Administration (NMPA) of China for chronic weight management in adults with obesity or overweight. The Phase 3 clinical trial of mazdutide in Chinese adults with overweight or obesity met primary and secondary endpoints, showing superiority over placebo in terms of body weight reduction and cardiometabolic endpoints. The safety profile was similar to previous clinical studies, with no new safety signals observed. The leading principal investigator of the study, Professor Linong Ji, emphasized the potential benefits of mazdutide in reducing chronic disease risks, and Dr. Lei Qian, Vice President of Clinical Development of Innovent, highlighted the potential of mazdutide as a next-generation GLP-1-based anti-obesity drug with robust weight-loss efficacy and cardiometabolic benefits.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Innovent Announces Retirement of CFO and Appointment of New CFO
Rhea-AI Summary
Innovent Biologics, Inc. (IVBIY) announced the retirement of CFO Mr. Ronald Hao Xi Ede after a seven-year tenure, with Ms. Fei You appointed as the new CFO. Mr. Ede will continue as an executive director and managing partner of the Company's funds. Ms. You brings over 20 years of experience in financial management and strategic investment. Innovent's Founder, Chairman, and CEO, Dr. Michael Yu, expressed gratitude towards Mr. Ede's contributions and welcomed Ms. You as the new CFO.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management
-
News
Innovent Announces the First Phase 3 Clinical Trial of Mazdutide in Chinese Adults with Overweight or Obesity Met the Primary and All Key Secondary Endpoints, and Plans to Submit NDA of Mazdutide to the NMPA
Rhea-AI Summary
Innovent Biologics, Inc. (Innovent) (HKEX: 01801) announces successful Phase 3 trial of mazdutide for weight management in Chinese adults with overweight or obesity, meeting primary and key secondary endpoints with positive safety profile.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
News
Innovent Dosed First Participant in Phase 3 Clinical Study (GLORY-2) of Mazdutide (IBI362) Higher Dose 9 mg in Chinese Adults with Obesity
Rhea-AI Summary
Innovent Biologics, Inc. (Innovent) (HKEX: 01801) announces the successful dosing of the first participant in a Phase 3 clinical trial of mazdutide, a dual agonist for Chinese adults with obesity, showing promising results from a Phase 2 study. The drug demonstrated an 18.6% placebo-adjusted mean percent reduction in body weight and multiple metabolic benefits in Chinese people with obesity.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
-
News
Innovent and Xuanzhu Enter into Clinical Trial Collaboration Investigating Combination Therapy of Sintilimab (PD-1 inhibitor) and A Novel ADC Candidate for Advanced Solid Tumors in China
Rhea-AI Summary
Innovent Biologics, Inc. (HKEX: 01801) and Xuanzhu Biopharma announce a clinical trial collaboration and supply agreement for the combination therapies of TYVYT® (sintilimab injection) with KM-501 for advanced solid tumors in China.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
-
News
Innovent and SanegeneBio Enter Strategic Collaboration to Develop siRNA Drug for the Treatment of Hypertension
Rhea-AI Summary
Innovent Biologics, Inc. (HKEX: 01801) and Sanegene Bio USA Inc. have entered into a collaboration agreement to co-develop SGB-3908, an siRNA drug candidate targeting angiotensinogen (AGT) for the treatment of hypertension. Innovent also obtains an exclusive option to license in the future development, manufacturing, and commercialization rights of SGB-3908. Both parties will leverage their respective strengths to accelerate the development and ensure the commercial success of this innovative siRNA drug candidate.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
News
Innovent and AnHeart Therapeutics Announce the National Medical Products Administration of China Has Granted Taletrectinib (ROS1 Inhibitor) Priority Review Designation
Rhea-AI Summary
Innovent Biologics, Inc. (HKEX: 01801) and AnHeart Therapeutics announced that the Center for Drug Evaluation of China's National Medical Products Administration has granted Priority Review Designation for the New Drug Application of taletrectinib, a next-generation ROS1 tyrosine kinase inhibitor, for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer who have been previously treated with ROS1 TKIs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
News
Innovent Announces Publication of Mazdutide (IBI362) Phase 2 Full Results in Chinese Patients with Overweight or Obesity in Nature Communications
Rhea-AI Summary
Innovent Biologics, Inc. (Innovent) (HKEX: 01801) announces the publication of Phase 2 clinical trial results for mazdutide, a GLP-1R/GCGR dual agonist, in Chinese patients with overweight or obesity in Nature Communications. The results show significant weight loss and multiple cardiovascular and metabolic benefits, with ongoing Phase 3 trials in progress.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
-
News
Innovent Announces Inclusion in the China National Reimbursement Drug List of TYVYT® 's Seventh Indication and BYVASDA®'s Eighth Indication
Rhea-AI Summary
Innovent Biologics, Inc. (HKEX: 01801) announces the inclusion of TYVYT® and BYVASDA® in the National Reimbursement Drug List (2023 Version) for the treatment of various cancers, expanding their coverage to benefit a broader range of patients. TYVYT® is the first and only PD-1 inhibitor approved for the treatment of EGFR-mutated locally advanced or metastatic non-squamous non-small cell lung cancer post EGFR-TKI therapy, while BYVASDA® is the only bevacizumab approved for the same indication. This update aligns with Innovent's mission of developing affordable high-quality biopharmaceuticals and supports the 'Healthy China 2030' strategy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
News
Innovent Biologics and Synaffix Expand ADC Collaboration Following Positive Preliminary Clinical Signal from Ongoing Phase 1 Study
Rhea-AI Summary
Innovent Biologics, Inc. (HKEX: 01801) expands licensing deal with Synaffix B.V., a Lonza company (SIX:LONN), to develop new ADC candidates using Synaffix's ADC technology, including GlycoConnect®, HydraSpace®, and toxSYN® linker-payloads. Innovent will focus on research, development, manufacturing, and commercialization of new ADC candidates. Synaffix will receive upfront payment, potential milestone payments, and royalties on commercial sales for each licensed target. Dr. Kaijie He, Vice President of Cancer Biology and ADC research at Innovent, expressed excitement about the expanded collaboration, while Peter van de Sande, Head of Synaffix, praised Innovent's R&D expertise and clinical development capabilities.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
Stock IVBIY logo
Innovent Biologics Inc

OTC:IVBIY

IVBIY Rankings

N/A Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

IVBIY Stock Data

7.84B
1.38B
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
China (Mainland)
Suzhou